4.7 Article

Worldwide barriers to genetic testing for movement disorders

期刊

EUROPEAN JOURNAL OF NEUROLOGY
卷 28, 期 6, 页码 1901-1909

出版社

WILEY
DOI: 10.1111/ene.14826

关键词

chorea; dystonia; genetic and inherited disorders; genetic diagnosis; genetic testing; movement disorders; Parkinson' s disease; whole exome sequencing

资金

  1. Roche-CHDI foundation ENROLL HD
  2. Fondazione di Sardegna
  3. Sanofi-Genzyme
  4. Biogen
  5. Biohaven
  6. Medtronic
  7. AbbVie Inc.
  8. Acadia Pharmaceuticals
  9. Allergan Inc.
  10. Biotek
  11. Cerevel Therapeutics
  12. CHDI Foundation
  13. Dystonia Coalition
  14. Emalex Biosciences Inc.
  15. F. Hoffmann-La Roche Ltd
  16. Huntington Study Group
  17. Medtronic Neuromodulation
  18. Merz Pharmaceuticals
  19. Michael J Fox Foundation for Parkinson Research
  20. National Institutes of Health
  21. Neuraly Inc.
  22. Neurocrine Biosciences
  23. Parkinson's Foundation
  24. Parkinson Study Group
  25. Prilenia Therapeutics
  26. Revance Therapeutics Inc.
  27. Teva Pharmaceutical Industries Ltd.
  28. International Parkinson's Disease and Movement Disorder Society
  29. Boston Scientific
  30. Merz and Global Kynetic
  31. US government (National Institutes of Health)
  32. Cure Dystonia Now
  33. Dystonia Study Group
  34. Cavion Therapeutics, Retrophin Inc.
  35. NIH from the National Institutes of Neurological Disorders and Stroke [NS116025, NS065701]
  36. NIH from the Office of Rare Diseases Research at the National Center for Advancing Translational Sciences [TR 001456]

向作者/读者索取更多资源

This study assessed global access to genetic testing for movement disorders and found limited availability in many regions compared to Europe and North America. Rates of access to genetic testing were below 50%, with Europe having the highest rate of free genetic testing. Major disparities in genetic testing access were highlighted among different world regions.
Background and purpose Despite enormous advances in identifying genetic variants responsible for many neurological diseases, access to genetic testing may be limited in clinical practice. The objective of this study was to assess worldwide access to genetic tests for movement disorders and factors impacting their utilization. Methods The Rare Movement Disorders Study Group of the International Parkinson and Movement Disorder Society designed an online survey electronically mailed to all 7815 members. Results Survey data completed by 1269 participants from 109 countries were analysed. Limited access to geneticists and genetic counsellors was reported in many world regions compared to Europe and North America. Availability of genetic testing was limited, with rates of access lower than 50%. Genetic testing for chorea was the most commonly available. For parkinsonism, dystonia, ataxia, hereditary spastic paraplegias and metabolic disorders, there was limited access to genetic testing in all countries compared to Europe and North America, with significant differences found for Africa, Central/South America, Asia. In many regions, genetic testing was supported by either private or public funding. Genetic testing was free of charge in Europe according to 63.5% of respondents. In North America, Africa, Central/South America, Asia and the Middle East access to free of charge genetic testing was by far significantly lower compared to Europe. Conclusions This survey highlights difficulties in accessing genetic testing and individuals with expertise in genetics at the worldwide level. In addition, major disparities in genetic testing amongst world regions are highlighted, probably due to a variety of factors including financial barriers.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据